Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | UBE2N | P61088 | 1/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18990510 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2LMNAHTTUBE2NMAPT | |
| SCHEMBL18989514 | 0.82 | MAPK1 (0.66) | SMN1; SMN2LMNAHTTUBE2NMAPT | |
| SCHEMBL18989807 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHTTMAPTTP53 | |
| SCHEMBL18990501 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAHTTUBE2NMAPT | |
| SCHEMBL18989539 | 0.78 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNAHTTUBE2NMAPT | |
| SCHEMBL21861569 | 0.78 | TRPA1 (0.77) | SMN1; SMN2LMNATRPA1MAPTCYP1A2 | |
| SCHEMBL17619850 | 0.78 | TRPA1 (1.00) | SMN1; SMN2LMNATRPA1MAPTCYP1A2 | |
| SCHEMBL17619604 | 0.76 | TRPA1 (0.70) | SMN1; SMN2TRPA1HIF1APOLB | |
| SCHEMBL18990448 | 0.76 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAHTTMAPTTP53 | |
| SCHEMBL660023 | 0.76 | ADORA2B (0.76) | SMN1; SMN2LMNATRPA1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-3389664-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | Raze Therapeutics Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | SMN1; SMN2 1247/4885LMNA 3559/4885HTT 539/4885 |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | SMN1; SMN2 1247/4885LMNA 3559/4885HTT 539/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | SMN1; SMN2 1247/4885LMNA 3559/4885HTT 539/4885 |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | SMN1; SMN2 1247/4885LMNA 3559/4885HTT 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.